Anixa Biosciences
ANIX
35 hedge funds and large institutions have $15.2M invested in Anixa Biosciences in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
32% more capital invested
Capital invested by funds: $11.5M → $15.2M (+$3.7M)
9% more funds holding
Funds holding: 32 → 35 (+3)
0.75% more ownership
Funds ownership: 9.86% → 10.61% (+0.75%)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
21% less call options, than puts
Call options by funds: $251K | Put options by funds: $317K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$396K |
| 2 |
State Street
Boston,
Massachusetts
|
+$305K |
| 3 |
Bank of New York Mellon
New York
|
+$250K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$226K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$189K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$473K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$78K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$75.1K |
| 4 |
Morgan Stanley
New York
|
-$60.5K |
| 5 |
BlackRock
New York
|
-$34.9K |
ANIX Hedge Fund Activity: Q3 2021 in Review
35 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q3 2021, worth a combined $15.2M — up 32% from $11.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ANIX positions and 4 closed out — a net gain of 3 holders — while 8 added to existing stakes and 10 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $396K. The largest seller was UBS Group, cutting an estimated $473K.
- 35 institutional investors held Anixa Biosciences (ANIX) as of Q3 2021, up from 32 in Q2 2021.
- Funds reported $15.2M of Anixa Biosciences stock for Q3 2021, up 32% quarter-over-quarter.
- 7 funds opened new Anixa Biosciences positions in Q3 2021 and 4 closed out, a net change of +3 holders.
- The largest Anixa Biosciences buyer in Q3 2021 was Renaissance Technologies, an estimated $396K added.
- The largest Anixa Biosciences seller in Q3 2021 was UBS Group, an estimated $473K sold.
Based on aggregated 13F filings for Q3 2021.